Terry D. Butters

Overview

Best Publications

• Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis

  T Cox;R Lachmann;C Hollak;J Aerts

  954
  Citations

• N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.

  Frances M. Platt;Gabrielle R. Neises;Raymond A. Dwek;Terry D. Butters

  585
  Citations

• Targeting glycosylation as a therapeutic approach

  Raymond A. Dwek;Terry D. Butters;Frances M. Platt;Nicole Zitzmann

  582
  Citations

• Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: Implications for the development of broad spectrum anti-hepatitis virus agents

  Nicole Zitzmann;Anand S. Mehta;Sandra Carrouée;Terry D. Butters

  477
  Citations

• Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N-Butyldeoxynojirimycin

  F M Platt;G R Neises;G Reinkensmeier;M J Townsend

  470
  Citations

• Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase.

  Michael A Simpson;Harold Cross;Christos Proukakis;David A Priestman

  447
  Citations

• Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.

  M Jeyakumar;R Thomas;E Elliot-Smith;D A Smith

  445
  Citations

• Inhibition of Glycosphingolipid Biosynthesis: Application to Lysosomal Storage Disorders

  Terry D. Butters;Raymond A. Dwek;Frances M. Platt

  397
  Citations

• Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease.

  Jean Pyo Lee;Mylvaganam Jeyakumar;Rodolfo Gonzalez;Hiroto Takahashi

  357
  Citations

• Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.

  M Jeyakumar;T D Butters;M Cortina-Borja;V Hunnam

  326
  Citations

• Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.

  Terry D. Butters;Raymond A. Dwek;Frances M. Platt

  321
  Citations

• Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.

  D. Elstein;C. Hollak;J. M. F. G. Aerts;S. van Weely

  311
  Citations

• N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing.

  F M Platt;G R Neises;G B Karlsson;R A Dwek

  279
  Citations

• Storage solutions: treating lysosomal disorders of the brain.

  Mylvaganam Jeyakumar;Raymond A. Dwek;Terry D. Butters;Frances M. Platt

  276
  Citations

• Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120.

  G B Karlsson;T D Butters;R A Dwek;F M Platt

  242
  Citations

• The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.

  P B Fischer;M Collin;G B Karlsson;W James

  223
  Citations

• Therapeutic applications of imino sugars in lysosomal storage disorders.

  Terry D. Butters;Raymond A. Dwek;Frances M. Platt

  216
  Citations

• N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo

  Ulrika Andersson;Terry D Butters;Raymond A Dwek;Frances M Platt

  203
  Citations

• Treatment with miglustat reverses the lipid-trafficking defect in Niemann–Pick disease type C

  Robin H Lachmann;Danielle te Vruchte;Emyr Lloyd-Evans;Gabriele Reinkensmeier

  199
  Citations

• Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling.

  David C.A Neville;Virginie Coquard;David A Priestman;Danielle J.M te Vruchte

  199
  Citations